A Phase Ib Open-Label Multicenter Study To Investigate

Recruiting

99 years or below

All

1 Location

Brief description of study

Requesting a reliance agreement with an external IRB. Study to evaluate pharmacokinetics, safety/tolerability, and immunogenicicty of ocrelizumab admistered subcutaneously in patients with MS. Pre-treated patients will be randomized (1:1) to dose-escalated, subcutaneous or IV administration. Treatment naive patients receive dose-escalated, subcutaneous administration only. All participants may then enter a dose continuation phase.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 12 Apr 2023. Study ID: 833380

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase Ib Open-Label Multicenter Study To Investigate The Pharmacokinetics Safety And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis

Brief description of study

Eligibility of study

Find a site

Interested in the study